CASE STUDY

SITE AND PATIENT SOLUTIONS

amrClinical
Patient Centered | Trusted Research

2024 Phase II Botulism Prevention Trial – 100% AMR Clinical Sites

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics & Immunogenicity of Compound in Adult Subjects

250
RANDOMIZED PATIENTS

1+ MONTH
ACCELERATED ENROLLMENT

85%
ALIGNED TO US CENSUS

ALL SITES
ENROLLED



Study Background

Indication: Botulism Prevention
Government funded (DoD) / CRO led

Adjusted Timelines:

- Study LPI (Plan): 07NOV24
- Study LPI (Actual): 01OCT24
- Study LPLV (Plan) 07MAR25
- Study LPLV (Actual) 22JAN25

14
AMR SITES

2
PHASE

18-65
YEARS OLD

AMR Clinical Highlights

- AMR Clinical selected as exclusive site company for protocol delivery and patient experience
- Engagement with AMR Clinical Project Delivery team resulted in:
  - Streamlined and effective communication
  - Proactive issue resolution
  - Minimized rework
- AMR Clinical / CRO maintained direct, frequent communication to manage forecast, avoid over-screening
- Flexibility to enroll patients as identified avoiding straight-line stratification of targets
- AMR Clinical accelerated enrollment targets and completed enrollment 1+ months early

Randomized Patients ~85% Aligned to US Census (2020)